Literature DB >> 2579317

Comparison of the cellular and RNA-dependent effects of sangivamycin and toyocamycin in human colon carcinoma cells.

M B Cohen, R I Glazer.   

Abstract

The effects of the pyrrolopyrimidine antibiotics sangivamycin and toyocamycin on the synthesis of RNA and protein, ribosomal RNA processing, and cell viability were examined in colon carcinoma cell line HT-29. Exposure for 24 hr to toyocamycin caused an exponential type of cell lethality resulting in a 4-log reduction of cell viability, while sangivamycin produced a gradual and self-limiting type of cell lethality resulting in a 1-log reduction of cell viability. Toyocamycin, at a concentration of 1 microM produced total cessation of precursor rRNA processing, while 10 microM sangivamycin produced little or no effect on processing. On the contrary, sangivamycin caused a significant decrease in protein synthesis after 6 hr, while toyocamycin had less effect. The inhibition of protein synthesis by sangivamycin results from an inhibition of the formation of complexes essential to the initiation of protein synthesis. The results suggest that the mechanisms of action of these closely related agents are quite distinct. The marked loss of cell viability caused by toyocamycin correlates with its effect on rRNA processing, while the slow inhibition of protein synthesis appears to be secondary to the loss of ribosome synthesis. On the other hand, the lesser cytotoxicity produced by sangivamycin results from a more direct effect on protein synthesis. Importantly, cells are much less capable of resuming normal proliferative activity after 24 hr of impaired rRNA processing than after a similar interval of reduced protein synthesis.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2579317

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  3 in total

1.  Selective CDK9 Inhibition by Natural Compound Toyocamycin in Cancer Cells.

Authors:  Somnath Pandey; Rahinatou Djibo; Anaïs Darracq; Gennaro Calendo; Hanghang Zhang; Ryan A Henry; Andrew J Andrews; Stephen B Baylin; Jozef Madzo; Rafael Najmanovich; Jean-Pierre J Issa; Noël J-M Raynal
Journal:  Cancers (Basel)       Date:  2022-07-08       Impact factor: 6.575

2.  ARC (NSC 188491) has identical activity to Sangivamycin (NSC 65346) including inhibition of both P-TEFb and PKC.

Authors:  Luke H Stockwin; Sherry X Yu; Howard Stotler; Melinda G Hollingshead; Dianne L Newton
Journal:  BMC Cancer       Date:  2009-02-20       Impact factor: 4.430

3.  The Development of Novel Therapies for the Treatment of Acute Myeloid Leukemia (AML).

Authors:  Sarit Assouline; Eftihia Cocolakis; Katherine L B Borden
Journal:  Cancers (Basel)       Date:  2012-11-02       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.